![]() |
|
|
Vol. 58, Issue 5, 895-902, November 2000
Department of Pharmacology (I.I., J.J.A.C., N.F., J.C.) and Neurosciences and Biomedical Sciences Programs (J.C.), School of Medicine, University of California, San Diego, La Jolla, California
| |
Abstract |
|---|
|
|
|---|
Lysophosphatidic acid (LPA) is a potent lipid mediator with diverse physiological actions on a wide variety of cells and tissues. Three cognate G-protein-coupled receptors have been identified as mammalian LPA receptors: LPA1/VZG-1/EDG-2, LPA2/EDG-4, and LPA3/EDG-7. The mouse forms of these genes were analyzed in rodent cell lines derived from nervous system cells that can express these receptors functionally. An efficient retrovirus expression system was used, and each receptor was heterologously expressed in B103 rat neuroblastoma cells that neither express these receptors nor respond to LPA in all assays tested. Comparative analyses of signaling pathways that are activated within minutes of ligand delivery were carried out. LPA induced cell rounding in LPA1- and LPA2-expressing cells. By contrast, LPA3 expression resulted in neurite elongation in B103 cells and inhibited LPA-dependent cell rounding in TR mouse neuroblast cells that endogenously express LPA1 and LPA2 but not LPA3. Each of the receptors could couple to multiple G-proteins and induced LPA-dependent inositol phosphate production, mitogen-activated protein kinase activation, and arachidonic acid release while inhibiting forskolin-induced cAMP accumulation, although the efficacy and potency of LPA varied from receptor to receptor. These results indicate both shared and distinct functions among the three mammalian LPA receptors. The retroviruses developed in this study should provide tools for addressing these functions in vivo.
| |
Introduction |
|---|
|
|
|---|
Lysophosphatidic
acid (LPA; 1-acyl-2-sn-glycerol-3-phosphate) is a simple,
yet potent, lipid mediator that exerts diverse biological effects on
many types of cells and tissues. It influences fundamental cellular
processes, which include proliferation, differentiation, survival, and
actin-based cytoskeletal alterations, and it has been proposed to be
involved in several clinical disorders, including ovarian cancer and
atherosclerosis (Moolenaar, 1995
, 1997
, 1999
). On a biochemical level,
LPA activates various signaling cascades, including activation of the
small GTPase Rho, phospholipase C (PLC), mitogen-activated protein
kinase (MAP kinase), and phosphoinositide 3-kinase (Moolenaar, 1995
,
1997
). In addition, LPA treatment can result in inhibition of adenylyl
cyclase activation. Recent progress in understanding the mechanisms
through which LPA exerts its effects has been accelerated by the
identification of several G-protein-coupled receptors that can account
for these LPA-dependent effects (Chun, 1999
; Chun et al., 1999
).
The identification of mouse and human
LPA1/VZG-1/EDG-2 as the first LPA receptor (Hecht
et al., 1996
; An et al., 1997
) has been complemented by the
identification of two related human LPA receptors:
LPA2/EDG-4 (An et al., 1998a
) and
LPA3/EDG-7 (Bandoh et al., 1999
; Im et al.,
2000
). We have independently characterized mouse genomic DNA for
lpA2 (Contos and Chun, 2000
) and
lpA3 (J. J. A. Contos and J. Chun,
in preparation). Genomic analyses of these three genes in mice
demonstrate high amino acid identity (47.7-51.9%) and similarity
(57.6-60.9%) among the three, as well as conserved intron-exon
boundaries in their genomic structures, all of which are consistent
with a common evolutionary origin. Contrasting with the three highly
related LPA receptors, a dissimilar receptor
cloned from Xenopus, PSP24, was reported to be a
high-affinity LPA receptor (Guo et al., 1996
). However, the functional
and physiological roles of this protein in mediating LPA signals in
mammals requires clarification and thus was not examined in this study.
When one considers that a single LPA1 receptor
can mediate multiple cellular responses (Fukushima et al., 1998
), the
existence of LPA2 and LPA3
receptors raises the question of how these receptors compare
functionally to one another. We have cloned cDNAs for LPA2 and LPA3 from a mouse
testis cDNA library (J. J. A. Contos and J. Chun, in
preparation). In the current study, each of the mouse receptor genes
was assayed using heterologous and overexpression approaches. We
selected murine neuronal cell lines to characterize the receptors
because previous work indicated that the nervous system is one of the
major loci of LPA1 receptor expression and function (Chun, 1999
), and both LPA2
and LPA3 receptor genes are also expressed in the
developing brain (J. J. A. Contos and J. Chun, in preparation).
This was made possible by the prior identification of the B103 rat
neuroblastoma cell line that does not express
LPA1 (Fukushima et al., 1998
),
LPA2 (Chun et al., 1999
), or
LPA3 receptors (J. J. A. Contos and J. Chun, unpublished observation) and it does not respond to LPA in
guanosine 5'-[
-thio]triphosphate binding, cell rounding,
serum-responsive element activation, and bromodeoxyuridine
incorporation (Fukushima et al., 1998
). This cell line does express
several heterotrimeric G-protein
-subunits thought to couple to
these LPA receptors, including G
i/o,
G
q/11, and G
13
(Fukushima et al., 1998
). Importantly, we report the use of a
retroviral expression system that provides several advantages over
transfection strategies: very high efficiency expression (approaching a
10-fold increase over previously used transfection efficiencies;
Fukushima et al., 1998
), single-copy/cell infection (Kang, 1995
) driven
by a common promoter, the ability to infect tissues in vivo, and
minimal cell death and damage compared with that encountered during
standard transfection approaches. Here we show comparative similarities
and differences in signaling responses for all three mammalian LPA receptors.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials.
[
-32P]ATP,
[
-32P]deoxy-CTP,
myo-[2-3H(N)]inositol,
[3H]arachidonic acid, and
125I-cAMP were purchased from NEN Life Science
Products (Boston, MA). LPA
(1-oleoyl-2-hydroxy-sn-glycero-3-phosphate) was purchased from Avanti Polar-Lipids (Alabaster, AL). Pertussis toxin (PTX), phorbol-12-myristate-13-acetate (PMA), U-73122, U-73433, and anti-cAMP polyclonal antibody were purchased from Calbiochem (La Jolla, CA). B103
rat noncortical neuroblastoma cells (Schubert et al., 1974
) were gifts
from Dr. David Schubert (The Salk Institute, La Jolla, CA). Retrovirus
expression vector (LZRS-EGFP) and Phoenix ecotropic retrovirus producer
cell lines were gifts from Dr. Garry P. Nolan (Stanford University,
Stanford, CA). Y-27632 was a gift from Yoshitomi Pharmaceutical
Industries (Saitama, Japan). The MAP kinase assay kit was purchased
from Stratagene (La Jolla, CA). Trizol and all cell culture reagents
were purchased from Life Technologies (Rockville, MD). Forskolin,
3-isobutyl-1-methylxanthine (IBMX), puromycin, anti-FLAG M2 monoclonal
antibody, and other reagents were purchased from Sigma (St. Louis, MO),
unless otherwise noted.
Construction of Retrovirus Vectors and Production of Retrovirus
Supernatants.
Mouse cDNA for lpA1 was
cloned as described (Hecht et al., 1996
). Mouse cDNAs for
lpA2 (Contos and Chun, 2000
) and
lpA3 (the deposited GenBank accession no.
AF293845; J. J. A. Contos and J. Chun, in preparation) were
cloned from Mouse Marathon-Ready testis cDNA from Clontech (Palo Alto,
CA). The entire open reading frame (ORF) of each receptor was subcloned
into the pFLAG-CMV-1 mammalian expression vector (Eastman Kodak Co.,
Rochester, NY) for introducing preprotrypsin-leader and FLAG-tag
sequences into an extracellular amino terminus of each receptor. These
sequences enabled higher expression levels of the receptors in the
plasma membrane (data not shown) and immunohistochemical detection of the receptors, respectively. Next, all coding sequences were cloned into a Moloney murine leukemia retrovirus vector, LZRS-EGFP (Dardalhon et al., 1999
), and complete inserts of the construct were confirmed by
sequencing. The sequences of all constructs are the same except for the
ORFs. Proviral organization of each construct is shown in Fig.
1A. The internal ribosome entry site
sequence permitted concomitant expression of the target gene and
enhanced green fluorescent protein (EGFP) gene from a single transcript
driven by a single 5'-long terminal repeat promoter. Retroviral
supernatants were prepared following the Nolan laboratory protocols
(Pear et al., 1997
). Each construct was transfected into ecotropic
Phoenix producer cells with DNA-calcium phosphate coprecipitation
methods. After 2 weeks in culture under puromycin (2 µg/ml)
selection, high-titer and helper-free retrovirus supernatants were
obtained and stored at
80°C until use.
|
Cell Culture and Retrovirus Infection.
B103 cells were
maintained as a monolayer culture on tissue culture dishes in
Dulbecco's modified Eagle's medium supplemented with 10%
heat-inactivated fetal calf serum (Hyclone, Logan, UT) and antibiotics.
TR mouse neocortical neuroblast cells (Chun and Jaenisch, 1996
) were
maintained as a monolayer culture in Opti-MEM I reduced-serum medium
supplemented with 2.5% heat-inactivated fetal calf serum, 20 mM
glucose, 55 µM 2-mercaptoethanol, and antibiotics. The viral
supernatant supplemented with 5 µg/ml hexadimethrine bromide was
added to the media of the cells on multiwell dishes, and the dishes
were centrifuged (700g) at 32°C for 1 h (referred to
later as the centrifugation method). The cells were cultured for
24 h, serum-starved for another day, and then used for each experiment. Effective infection was confirmed by EGFP fluorescence of
the infected cells. For the immunostaining shown in Fig.
2A, cells were seeded onto glass
coverslips (12-mm diameter) coated with 1.5 µg of Cell-Tak (Becton
Dickinson Labware, Bedford, MA) according to manufacturer's protocols.
|
Northern Blot Analysis. Cells on six-well dishes were washed once with phosphate-buffered saline (PBS) and solubilized in 1 ml of Trizol. Total RNA was isolated following the instructions by Life Technologies, and 15 µg of each RNA were separated on 6% formaldehyde/1% agarose gels. After transferring to a GeneScreen Plus Hybridization Transfer membrane (NEN), hybridization was performed at 55°C for 16 h in the hybridization buffer [25% (v/v) formamide, 5% SDS, 1% bovine serum albumin (BSA), 0.5 M Na2HPO4, 1 mM EDTA, and 100 µg/ml salmon sperm DNA]. The specific probes used were the NheI-XhoI fragments of the pEGFP-Tub vector (Clontech) for EGFP and the entire ORF cDNA for lpA1, lpA2, and lpA3. The probes were radiolabeled with [32P]-deoxy-CTP by conventional random primer-labeling methods.
Western Blot Analysis. TR cells on six-well dishes were washed once with PBS and then solubilized in the sample buffer [50 mM Tris-HCl (pH 6.8), 2% SDS, 6% (w/v) 2-mercaptoethanol, and 10% (w/v) glycerol]. The sample was sonicated three times for 5 s each with 10-s intervals on ice, using the Micro-ultrasonic cell disrupter (KONTES, Vineland, NJ) with the following settings: power 4, tune 4. The sonicated sample was separated on a 10% SDS-polyacrylamide gel and transferred to the Protran nitrocellulose membranes (Schleicher & Schuell, Keene, NH). The FLAG-tagged proteins were detected with anti-FLAG antibody using the Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA) and ECL Plus detection system (Amersham Pharmacia Biotech, Piscataway, NJ).
Immunostaining.
Cells were fixed with 4%
paraformaldehyde and permeabilized with 0.1% (w/v) Triton X-100/10%
(v/v) normal goat serum (Vector) in PBS. EGFP protein was detected with
anti-GFP polyclonal antibody (Clontech) and fluorescein
isothiocyanate-conjugated anti-rabbit IgG antibody (Vector).
FLAG-tagged receptor was detected with anti-FLAG antibody and
Cy3-conjugated anti-mouse IgG antibody (Jackson ImmunoResearch
Laboratories, West Grove, PA). The cells were observed under a Zeiss
Axiovert S100 or Axioplan 2 microscope with Zeiss Fluar 20× or
Plan-Apochromat 63× oil-immersion objective lens and the fluorescent
images were taken with MC100 microscope cameras (Carl Zeiss, Thornwood,
NY). To measure cell length, the infected cells on 24-well dishes were
stimulated with LPA, fixed, and stained with anti-GFP antibody. The
fluorescent images of the cells were collected into a Apple Power
Macintosh G4 computer with DEI-47 cooled charge-coupled device color
camera (Carl Zeiss) and the Scion Image software (Scion Corp.,
Frederick, MD). The cell lengths were measured using the Scion Image,
and percentages in five size pools (
40, 41-70, 71-100, 101-130,
and
131 µm) were determined with 100% as total cells counted
(>200 EGFP-positive cells on each well). The cells with
40-µm cell
lengths are not necessarily the rounded cells.
PLC Assay.
B103 cells on 12-well dishes were prelabeled with
[3H]inositol (2 µCi/well) for 24 h in
inositol-free Dulbecco's modified Eagle's medium. The cells were then
incubated for 30 min in Hepes/ Tyrode's/BSA buffer (Ishii et al.,
1997
) containing 10 mM LiCl and stimulated with LPA. After a 15-min
incubation, the reaction was terminated by aspirating the buffer and
adding 500 µl of ice-cold 0.4 M HClO4. After
standing on ice for 20 min, the 400-µl supernatant was neutralized with 200 µl of 0.72 N KOH/0.6 M KHCO3. The
precipitated material was removed by centrifugation, and the
supernatant was applied to an AG anion exchange column (1-X8, 100-200
mesh, formate form from Bio-Rad Laboratories, Hercules, CA; Ishii et
al., 1997
). Inositol phosphate fractions (IP1 + IP2 + IP3) of the samples were eluted
with the stepwise gradients of ammonium formate (Berridge et al.,
1983
).
Measurement of Intracellular cAMP Contents. B103 cells on 24-well dishes were incubated in Hepes/Tyrode's/BSA buffer containing 0.5 mM IBMX for 20 min. The cells were stimulated for 20 min with or without 1 µM forskolin in the presence or absence of various concentrations of LPA. The reaction was terminated by aspirating the buffer and adding 250 µl of 0.1 N HCl. After a 20-min extraction, supernatant was collected for the determination of cAMP contents with a radioimmunoassay using anti-cAMP antibody and 125I-cAMP, following Calbiochem protocols.
MAP Kinase Assay.
B103 cells on 12-well dishes were
stimulated by LPA or PMA. After a 10-min stimulation, the cells were
lysed in the lysis buffer [20 mM Tris-HCl (pH 8.0), 20 mM
-glycerophosphate, 1 mM sodium orthovanadate, 2 mM EGTA (pH 8.0), 2 mM dithiothreitol, and 0.1 mM phenylmethylsulfonyl fluoride] and
quickly frozen with liquid nitrogen. The cell extract was assayed for
its activity to phosphorylate-specific MAP kinase substrate,
PHAS-I protein (Haystead et al., 1994
), following the protocols
of Stratagene. The radioactivity in PHAS-I 21-kDa proteins on
SDS-polyacrylamide gels was measured using the AMBIS radioanalytic
imaging system (AMBIS Systems, San Diego, CA).
Arachidonic Acid Release.
B103 cells on 12-well dishes were
prelabeled for 24 h with [3H]arachidonic
acid (0.2 µCi/well) in Dulbecco's modified Eagle's medium. The
cells were subjected to a 20-min arachidonic acid release assay as
described previously (Ishii et al., 1997
, 1998
).
Statistical Analysis. Results shown are representative of at least three experiments. Data are the means ± S.E. of the triplicate samples. Statistical analysis was performed by ANOVA and a post hoc analysis was done with the Fisher's protected least significant difference test using StatView software (Abacus Concepts, Berkeley, CA).
| |
Results |
|---|
|
|
|---|
Establishment of a Retrovirus Expression System.
Mouse
lpA1, lpA2, and
lpA3 cDNAs were epitope tagged with FLAG
sequences at the extracellular amino terminus, and the constructs were
introduced into the retroviral vector. Ecotropic Phoenix packaging cell
lines were used to obtain high-titer, helper-free retroviral
supernatants that coexpressed a given LPA receptor with EGFP (but not a
LPA receptor-EGFP fusion protein), providing identification of receptor
expression in living and fixed cells using fluorescence microscopy.
These retroviruses were used to express each of the three
LPA receptors in two neuronal cell lines: B103
rat neuroblastoma cells that were derived from noncortical regions
(Schubert et al., 1974
) and TR mouse neuroblast cells that were derived
from the cerebral cortex (Chun and Jaenisch, 1996
).
|
LPA1 and LPA2, but Not LPA3,
Mediate LPA-Induced Cell Rounding.
B103 cells heterologously
expressing each receptor were treated with 1 µM LPA for 15 min,
stained for EGFP and FLAG epitope, and then observed for morphological
changes compared with controls (Fig. 2A). Percentages of infected cells
that had rounded morphology were determined in both untreated and
LPA-treated samples. Infection with LPA1 or
LPA2 virus slightly increased the population of
the rounded cells before exogenous LPA application (
10%; Fig. 3A). LPA application induced cell rounding in cells expressing
LPA1 or LPA2 in a
concentration-dependent manner (EC50
approximately 10 nM; Fig. 3A, left). However, infection of B103 cells
with LPA3 virus resulted in neurite elongation
(Fig. 2B), and LPA-induced cell rounding was not observed (Fig. 3A).
Expression of LPA3 significantly increased both
the number of cells with elongated neurites and the average cell length
(Fig. 2B). The population of LPA3-expressing cells with elongated (
131 µm) neurites increased more than 6-fold compared with controls, whereas the average length of these cells increased more than 60% (Fig. 2B). Neither parameter was affected by
LPA application in LPA3-expressing cells.
All LPA Receptors Mediate PLC Activation.
Next, we examined
the effectiveness of each of the receptors in mediating PLC activation,
an LPA response previously shown in fibroblasts (van Corven et al.,
1989
; Plevin et al., 1991
) and human LPA1- or
LPA2-expressing HTC4 rat hepatoma cells (An et
al., 1998b
). PLC activation leads to the production of two second
messengers, diacylglycerol and inositol triphosphate, the latter of
which can be followed using radioisotope labeling. B103 cells were
labeled with [3H]inositol for 24 h in
inositol-deficient medium and then stimulated with LPA, and the
radioactivity in the inositol phosphate fractions was measured (Fig.
4). LPA activated inositol phosphate
production in LPA1-, LPA2-
and LPA3-expressing cells, but not in control B103 cells, in a concentration-dependent manner. In all cases, this
activation was significantly inhibited by pretreatment with a
PLC-specific inhibitor (U-73122) but not with its structurally related
inactive analog (U-73343). This activation was not inhibited by
pretreatment with Y-27632 or PTX.
|
All LPA Receptors Mediate Inhibition of Adenylyl Cyclase.
LPA
has been shown to inhibit adenylyl cyclase activity in fibroblasts (van
Corven et al., 1989
), TR cells (Hecht et al., 1996
), human
LPA1- or LPA2-expressing
HTC4 cells (An et al., 1998b
), and mouse
LPA1-expressing RH7777 rat hepatoma cells (Im et
al., 2000
) via a PTX-sensitive pathway. In contrast, LPA increased forskolin-induced cAMP accumulation in human
LPA2- or LPA3-expressing Sf9 insect cells in a PTX-insensitive manner (Bandoh et al., 1999
). We
therefore examined which of the mouse LPA receptors mediated inhibition
or activation of adenylyl cyclase activity (Fig.
5). In
LPA1-expressing B103 cells, LPA potently
inhibited forskolin-induced cAMP accumulation (maximum 80% inhibition
at 10 µM). In LPA2- and
LPA3-expressing cells, LPA also inhibited
forskolin-induced cAMP accumulation, but both potency and efficacy were
lower than those in LPA1-expressing cells. These
effects were completely abolished by PTX pretreatment but were not
affected by Y-27632 pretreatment (data not shown). LPA did not increase
basal cAMP content in the cells expressing any of the three LPA
receptors (Fig. 5B).
|
All LPA Receptors Mediate MAP Kinase Activation and Arachidonic
Acid Release.
LPA has been shown to stimulate MAP kinase
activation in fibroblasts (Kumagai et al., 1993
; Hordijk et al., 1994
)
and LPA2- expressing PC12 rat pheochromocytoma
cells (Bandoh et al., 1999
). LPA-induced MAP kinase activation via each
LPA receptor was examined in B103 cells. After
10-min of LPA stimulation, the cells were quickly lysed and MAP kinase
activity in the lysate was determined via PHAS-I phosphorylation
activity. LPA induced MAP kinase activation in B103 cells expressing
any of the three LPA receptors but not in the
control cells (Fig. 6A). LPA effects in
each of the samples were small but significant (P < .05) and were comparable with those of PMA, a potent activator of
protein kinase C and MAP kinase. These LPA effects were completely
abolished with the PTX pretreatment. In PTX-pretreated cells expressing
any of the LPA receptors, LPA induced inhibition
of MAP kinase by unknown mechanisms.
|
| |
Discussion |
|---|
|
|
|---|
The molecular cloning of mammalian LPA receptors (Hecht et al.,
1996
; An et al., 1997
, 1998a
; Bandoh et al., 1999
; Im et al., 2000
) has
furthered our understanding of the versatility of this simple lipid.
The existence of multiple receptors suggests distinct receptor
functions in vivo. In this study, we used a retroviral system to
express these receptors heterologously within cells from the same or
similar species as the assayed receptor gene. Unlike prior studies,
including our own, that relied on either small percentages (<5-10%)
of transfected cells in transient assays, or possible clonal variations
associated with stable cell lines, this approach provides both improved
expression efficiency and reduced physical insult to cells. These
benefits should provide a better approximation of how these receptors
can signal, and this retroviral system should be suitable for future
studies in vivo. In the present study, we focused only on short-term
responses (all within 10-20 min after LPA application) in an effort to
eliminate indirect effects potentially encountered with prolonged
assays such as those used for cell proliferation.
Five signaling pathways were examined, of which three were activated
similarly by each LPA receptor. Each receptor
mediates inositol phosphate production in a Rho-independent and
Gi/o-independent fashion (Fig. 4), consistent
with Gq activation of PLC. Activation of all
three receptors also inhibited forskolin-induced cAMP accumulation (Fig. 5A), consistent with the expected interaction with
Gi/o. LPA receptors also
activated MAP kinase (Fig. 6A), and this also appears to be mediated
through Gi/o, based on results from PTX pretreatment that completely abolished MAP kinase activation. In
addition, LPA1 and LPA2
both similarly activated arachidonic acid release and cell rounding.
Arachidonic acid release for these two receptors was decreased but not
abolished by PTX pretreatment, suggesting activation of a
PTX-insensitive G-protein(s). The involvement of
Gi/o was expected, because MAP kinase is
suggested to be involved in agonist-induced cytosolic phospholipase
A2 activation that leads to arachidonic acid
release (Kramer and Sharp, 1997
; Gijaon and Leslie, 1999
), and MAP
kinase activation was PTX sensitive (Fig. 6A). The mechanism by which
LPA1 and LPA2 produce
arachidonic acid release may also use the Gq/PLC
pathway, because LPA-induced arachidonic acid release was not
completely PTX sensitive (Fig. 6B).
Cell rounding constituted a second response that was shared by
LPA1 and LPA2. We
previously showed that LPA1 mediates cell rounding in B103 cells in a Rho-dependent manner (Fukushima et al.,
1998
), and here we found that LPA2 similarly
mediates this response (Fig. 3A, left). The G-proteins that likely
mediate these Rho-activating effects are
G12/13-type proteins.
G
12 and G
13 have been
shown to interact with p115 RhoGEF, the Rho guanine nucleotide exchange
factor (Hart et al., 1998
; Kozasa et al., 1998
). We observed that, even
without LPA application, LPA1 or LPA2 expression significantly increased the
numbers of rounded cells in the TR cell lines (Fig. 3A, right). This is
not surprising because overexpression of G-protein-coupled receptors
can lead to a constitutive activation in the absence of agonists (Bond et al., 1995
; Ishii et al., 1997
). The presence of endogenous LPA could
also result in receptor activation in some cells.
In contrast to the similarities among LPA1,
LPA2, and LPA3 that we have
reported thus far, differences were also observed. In several assays,
quantitative differences could be identified. These data must be
interpreted with caution, because it was not possible to express
identical amounts of each receptor protein, despite similar levels of
mRNA transcription (Fig. 1B). Nevertheless, reduced levels of
LPA2 expression compared with the other two receptors (Figs. 1C and 2A) may be what occurs normally in vivo, because a similar reduction in protein expression was previously observed (Bandoh et al., 1999
). For two of the five examined signaling responses, qualitative differences were observed for
LPA3. Arachidonic acid release was differentially
affected by PTX pretreatment. It completely abolished LPA-induced
release in LPA3-expressing cells but not in
LPA1- and LPA2-expressing
cells (Fig. 6B). This result suggests that LPA3
preferentially utilizes Gi/o in arachidonic acid
release, whereas LPA1 and
LPA2 also utilize a PTX-insensitive G-protein(s).
Most striking, however, was the effect of LPA3 on cell morphology compared with LPA1 and LPA2. LPA3 expression in B103 cells did not induce cell rounding. This lack of effect was not due to nonfunctional receptors, because LPA3 stimulated other examined pathways in an LPA-dependent manner. In addition, LPA3 partially inhibited LPA-induced cell rounding when expressed in TR cells that endogenously express LPA1 and LPA2 (Fig. 3A, right). Furthermore, LPA3 expression produced marked neurite elongation in both B103 (Fig. 2) and TR cells (data not shown). Neurite elongation was independent of LPA concentration. A hypothetical mechanism that could explain these results is inhibition of Rho activity, because neurite elongation was observed in B103 and TR cells exposed to only the Rho kinase inhibitor, Y-27632, alone (data not shown). If this were true, then neurite elongation could be considered a default state augmented by comparatively low Rho activity. The biological role of LPA3 in such a process is currently unclear.
Our results are in general agreement with prior work on
LPA1 and LPA2 receptors (An
et al., 1998b
) and complement recent reports on
LPA1, LPA2, and
LPA3 receptors (Bandoh et al., 1999
; Im et al.,
2000
), although there are several differences in technical approach and
results. First, a potentially important detail is that there are
isoforms of LPA receptors. The second LPA receptor encoded by the gene
edg-4 (An et al., 1998a
,b
) varies significantly in the
carboxyl terminus compared with mouse and human
lpA2 clones (Contos and Chun, 2000
). This
initially characterized gene contains a frame-shift mutation associated
with an ovarian tumor, the source of cDNA for their expression
constructs. Direct comparisons of the normal and mutant forms of
LPA2 were not examined here. Our data indicate a
close functional similarity between LPA1 and
normal LPA2, including similar responses in all
of the assays examined.
Second, prior studies obtained results in Sf9 insect cells infected
with baculovirus to express mouse LPA1 (Zondag et
al., 1998
) or human LPA1,
LPA2, and LPA3 (Bandoh et
al., 1999
). In these systems, both mouse and human
LPA1 receptors were nonfunctional, underscoring
probable incompatibilities with the available insect G-proteins and
LPA1 receptors. Differences in such downstream signaling components may also explain the observation of
increased forskolin-induced cAMP accumulation in
LPA2- and LPA3-expressing Sf9 cells, compared with our data in which all
LPA receptors mediate LPA-dependent inhibition of
forskolin-induced cAMP accumulation. Interestingly, mouse
LPA1, but not human LPA2
and LPA3, receptors mediated inhibition in
forskolin-induced cAMP accumulation in RH7777 cells (Im et al., 2000
),
suggesting the different signaling properties in neuronal cells and
hepatic cells.
A third difference was observed in examining PC12 cells in which human
LPA2, but not LPA1 and
LPA3, induced MAP kinase-mediated Elk1 (Marais et
al., 1993
) activation (Bandoh et al., 1999
), whereas we found that all
LPA receptors activate MAP kinase. There are likely biological
differences between PC12 cells that are derived from the adrenal
medulla and the central nervous system cells utilized here. For
example, PC12 cells undergo cell rounding via both a Rho-dependent and
Gq-dependent mechanism (Katoh et al., 1998
),
whereas in B103 cells, Gq activation was not
sufficient for cell rounding based on data using
LPA3 receptor (Figs. 3A, left, and 4). These
differences in receptor responses might be explained by amino acid
sequence variation between mouse and human LPA1,
LPA2, and LPA3 (97.3, 90.8, and 90.8% identity, respectively).
Multiple LPA receptors with shared signaling properties could provide
cells with overlapping properties for essential functions. Additionally, distinct signals, as observed here for
LPA3, could underscore more specialized
functions. One possible specialized function we observed was the
morphological effects of LPA3, which, in contrast
to LPA1 and LPA2, did not
produce cell rounding and actually promoted neurite elongation. Because
the developing nervous system is one of the major loci for
LPA receptor expression (Chun, 1999
; J. J. A. Contos and J. Chun, in preparation), the functional antagonism
for cell rounding could have consequences for neural development. All
of the receptors are expressed in the brain, but there is a variation
of both spatial and temporal expression patterns. For example,
lpA1 is expressed in neuroblasts during embryonic development (Hecht et al., 1996
) but in oligodendrocytes and
Schwann cells at later ages (Weiner et al., 1998
; Weiner and Chun,
1999
). Other developmental and spatial patterns of expression appear to
occur for both lpA2 and
lpA3 (J. J. A. Contos and J. Chun,
in preparation). The recent demonstration that LPA increases Alzheimer's disease-like Tau phosphorylation accompanied by neurite retraction in SY-SH5Y human neuroblastoma cells (Sayas et al., 1999
)
suggests that LPA1 or LPA2
receptor signaling may be involved in some neuronal disorders.
Information concerning their expression in a single cell, or single
cell type, is only just emerging, and there exists the additional
possibility of receptor combinatorial functions or synergism in cells
expressing more than one receptor that could further modify cellular
responses to LPA.
| |
Acknowledgments |
|---|
We thank Dr. Joan Heller Brown (University of California, San Diego) for reading the manuscript. We also thank Carol Akita for technical assistance, Drs. Yuka Kimura, Maria Pompeiano, Joshua Weiner, and Guangfa Zhang for discussions, and Casey Cox for copyediting the manuscript.
| |
Footnotes |
|---|
Received May 15, 2000; Accepted August 2, 2000
This work was supported by the National Institute of Mental Health (R01 MH51699) and the National Institutes of Health (K02 MH01723) (to J.C.). I.I. and N.F. are supported by the Uehara Memorial Foundation.
Send reprint requests to: Jerold Chun, M.D., Ph.D.. Department of Pharmacology, School of Medicine, University of California, San Diego, 9500 Gilman Dr., La Jolla, CA 92093-0636. E-mail: jchun{at}ucsd.edu
| |
Abbreviations |
|---|
LPA, lysophosphatidic acid; EGFP, enhanced green fluorescent protein; IBMX, 3-isobutyl-1-methylxanthine; MAP kinase, mitogen-activated protein kinase; ORF, open reading frame; PBS, phosphate-buffered saline; PLC, phospholipase C; PMA, phorbol-12-myristate-13-acetate; PTX, pertussis toxin; BSA, bovine serum albumin; PHAS-I, phosphorylated heat- and acid-stable protein-I.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
R. M. Kortlever, T. R. Brummelkamp, L. A. van Meeteren, W. H. Moolenaar, and R. Bernards Suppression of the p53-Dependent Replicative Senescence Response by Lysophosphatidic Acid Signaling Mol. Cancer Res., September 1, 2008; 6(9): 1452 - 1460. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Friis, K. G. Vorum, and I. H. Lambert Volume-sensitive NADPH oxidase activity and taurine efflux in NIH3T3 mouse fibroblasts Am J Physiol Cell Physiol, June 1, 2008; 294(6): C1552 - C1565. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. C. de Sampaio e Spohr, J. W. Choi, S. E. Gardell, D. R. Herr, S. K. Rehen, F. C. A. Gomes, and J. Chun Lysophosphatidic Acid Receptor-dependent Secondary Effects via Astrocytes Promote Neuronal Differentiation J. Biol. Chem., March 21, 2008; 283(12): 7470 - 7479. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Murph, J. Hurst-Kennedy, V. Newton, D. N. Brindley, and H. Radhakrishna Lysophosphatidic Acid Decreases the Nuclear Localization and Cellular Abundance of the p53 Tumor Suppressor in A549 Lung Carcinoma Cells Mol. Cancer Res., November 1, 2007; 5(11): 1201 - 1211. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Yanagida, S. Ishii, F. Hamano, K. Noguchi, and T. Shimizu LPA4/p2y9/GPR23 Mediates Rho-dependent Morphological Changes in a Rat Neuronal Cell Line J. Biol. Chem., February 23, 2007; 282(8): 5814 - 5824. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-W. Lee, R. Rivera, A. E. Dubin, and J. Chun LPA4/GPR23 Is a Lysophosphatidic Acid (LPA) Receptor Utilizing Gs-, Gq/Gi-mediated Calcium Signaling and G12/13-mediated Rho Activation J. Biol. Chem., February 16, 2007; 282(7): 4310 - 4317. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Herr, N. Grillet, M. Schwander, R. Rivera, U. Muller, and J. Chun Sphingosine 1-Phosphate (S1P) Signaling Is Required for Maintenance of Hair Cells Mainly via Activation of S1P2 J. Neurosci., February 7, 2007; 27(6): 1474 - 1478. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-W. Lee, R. Rivera, S. Gardell, A. E. Dubin, and J. Chun GPR92 as a New G12/13- and Gq-coupled Lysophosphatidic Acid Receptor That Increases cAMP, LPA5 J. Biol. Chem., August 18, 2006; 281(33): 23589 - 23597. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Tsukahara, R. Tsukahara, S. Yasuda, N. Makarova, W. J. Valentine, P. Allison, H. Yuan, D. L. Baker, Z. Li, R. Bittman, et al. Different Residues Mediate Recognition of 1-O-Oleyllysophosphatidic Acid and Rosiglitazone in the Ligand Binding Domain of Peroxisome Proliferator-activated Receptor {gamma} J. Biol. Chem., February 10, 2006; 281(6): 3398 - 3407. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. M. Urs, K. T. Jones, P. D. Salo, J. E. Severin, J. Trejo, and H. Radhakrishna A requirement for membrane cholesterol in the {beta}-arrestin- and clathrin-dependent endocytosis of LPA1 lysophosphatidic acid receptors J. Cell Sci., November 15, 2005; 118(22): 5291 - 5304. [Abstract] [Full Text] [PDF] |
||||